Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP Variants. (GENEPI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04122742
Recruitment Status : Recruiting
First Posted : October 10, 2019
Last Update Posted : January 9, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Bordeaux

Brief Summary:

Rubinstein-Taybi syndrome (RSTS) is a rare and severe congenital developmental disorder characterized by congenital anomalies and intellectual disability with a long term memory deficit. The main challenge is to improve the intellectual and memory efficiency of these patients. CREBBP and EP300 are the two genes known to cause RSTS. Both paralogs play a major role in chromatin remodeling and encode for transcriptional co-activators interacting with many proteins.

The aim of this pilot study is to characterize the histone acetylation profiles in order to identify specific acetylation markers during normal and pathological neuronal differentiation of cortical and pyramidal neurons in RSTS.


Condition or disease Intervention/treatment
Rubinstein-Taybi Syndrome Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included. Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations Other: Functional involvement of identified epigenetic alterations Biological: Culture of lymphoblastoid line from blood sample

Detailed Description:

CREBBP and EP300 are the two paralog genes associated with RSTS determinism and code for CBP and p300, respectively. These proteins are transcriptional coactivators that possess a catalytic lysine acetyl transferase (KAT) domain involved in the acetylation of lysine residues of histones but also other proteins. CBP and p300 promote transcription by creating a chromatin environment that is favorable for gene expression and by linking different transcription factors to each other. They thus orchestrate the regulation of the transcription machinery, from the basal promoter to the enhancers of the target genes.

RSTS is considered a genetic model of neurodevelopmental anomaly with an epigenetic component.

Histone acetylation is one of the major post-translational modifications (PTMs) of these proteins that provide for the formation and control of chromatin structure. When differentiating embryonic cells, this modification plays a key role in transcriptional activation.

The mouse models of RSTS have made the link between the modulation of histone acetylation and the formation of memory by showing their key role in neuronal plasticity. However no data exists on the acetylation of histones in the neurons of RSTS patients. Furthermore, in humans, the molecular pathways impacted by these alterations during neurodevelopment are not specified, especially in the pyramidal neurons which are the precursors of hippocampal neurons involved in the encoding and storage of memory.

In RSTS a loss of CBP function results in a deficit in KAT activity, which is responsible for altering histone acetylation, leading to inappropriate changes in chromatin structure. The consequence of a mutation is a result of a deregulation of the activity of genes involved in development. No neuronal level studies are currently available on the functional link between histone acetylation and deregulated genes in the RSTS.

In this project, investigators will identify target genes whose epigenetic regulation is mediated by histone acetylation. More specifically, the study will focus on chromatin dynamics during normal and pathological neuronal differentiation of cortical and pyramidal neurons. Investigators will determine among the CBP-dependent histone markers, those that are modified in RSTS patients cells and the loci they control. In parallel, investigators will define genes whose neuronal expression is altered in RSTS patients.

The integration of all these data will allow us to specify which genes are deregulated during neuronal differentiation as a consequence of CBP lysine acetyltransferase function loss.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 4 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP Variants.
Actual Study Start Date : October 8, 2019
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2020


Group/Cohort Intervention/treatment
Patients with RSTS Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.
Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.

Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy
induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons

Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations
Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing

Other: Functional involvement of identified epigenetic alterations
Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.

Biological: Culture of lymphoblastoid line from blood sample
Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation




Primary Outcome Measures :
  1. Identification of a specific acetylation profile of RSTS [ Time Frame: Inclusion visit ]

    From skin biopsy sample collected at inclusion visit :

    • No assumptions about the number of histone marks needed to define the profile
    • Will be retained as the specific mark of the disease if it is 100% present in the cases and 100% absent in the controls
    • The specific profile can be defined in one or more stages of cell differentiation: iPSC - neuronal progenitor - cortical and pyramidal neurons


Secondary Outcome Measures :
  1. Identification of different target genes between SRT patients and controls [ Time Frame: Inclusion visit ]
    SRT patients will be compared to 4 control cell cultures from healthy volunteers matched for age and sex already available

  2. Evidence of a significantly different level of expression for common target genes for RSTS patients and controls [ Time Frame: Inclusion visit ]

Biospecimen Retention:   Samples With DNA
skin biopsy and whole blood sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with a clinical and molecular diagnosis of RSTS having a specialized consultation in CHU de Bordeaux
Criteria

Inclusion Criteria:

  • Patient with a clinical and molecular diagnosis of RSTS
  • Patients carrying the CREBBP gene mutation: c.3832C> T / p.Glu1278Lys.
  • Patients older than 10 years
  • Affiliated patients or beneficiaries of a social security scheme.
  • Free, informed and signed consent by the parents or holder of parental authority for minor patients
  • Free, informed and signed consent by the patient representative for the major patients under guardianship

Exclusion Criteria:

Patients having:

  • a history of allergy to any product or device that may be used before, during, and after the biopsy;
  • cutaneous disease of the areas where the biopsy is to be performed
  • underwent physical treatment (radiotherapy, ...) on the area to be biopsied, during the last 6 months
  • hereditary or acquired disorders of hemostasis

Patients under treatment:

  • likely to act on the haemostasis (anticoagulants, platelet antiaggregants, ...) in the month preceding the inclusion and during the study
  • by histone deacetylase inhibitor (sodium valproate) likely to interfere with the interpretation of the results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04122742


Contacts
Layout table for location contacts
Contact: Julien VAN-GILS +33 5 57 82 03 53 julien.van-gils@chu-bordeaux.fr
Contact: Noémie BRONNEC +335 57 82 03 45 noemie.bronnec@chu-bordeaux.fr

Locations
Layout table for location information
France
Centre Hospitalier Universitaire de Bordeaux Recruiting
Talence, France, 33400
Contact: Julien VAN-GILS    +33 5 57 82 03 53    julien.van-gils@chu-bordeaux.fr   
Contact: Noémie BRONNEC    +335 57 82 03 45    noemie.bronnec@chu-bordeaux.fr   
Sponsors and Collaborators
University Hospital, Bordeaux

Layout table for additonal information
Responsible Party: University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT04122742    
Other Study ID Numbers: CHUBX 2019/19
First Posted: October 10, 2019    Key Record Dates
Last Update Posted: January 9, 2020
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Bordeaux:
Epigenetics
Acetylation
Diagnostic
Induced pluripotent stem cells
Rubinstein-Taybi syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Rubinstein-Taybi Syndrome
Dysostoses
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Craniofacial Abnormalities
Musculoskeletal Abnormalities
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn